Switch to:

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 5/10

vs
industry
vs
history
Cash to Debt No Debt
CYTR's Cash to Debt is ranked higher than
96% of the 832 Companies
in the Global Biotechnology industry.

( Industry Median: 56.40 vs. CYTR: No Debt )
Ranked among companies with meaningful Cash to Debt only.
CYTR' s 10-Year Cash to Debt Range
Min: 2.95   Max: No Debt
Current: No Debt

Interest Coverage No Debt
CYTR's Interest Coverage is ranked higher than
93% of the 384 Companies
in the Global Biotechnology industry.

( Industry Median: 10000.00 vs. CYTR: No Debt )
Ranked among companies with meaningful Interest Coverage only.
CYTR' s 10-Year Interest Coverage Range
Min: 9999.99   Max: 9999.99
Current: No Debt

F-Score: 4
Z-Score: -1.42
M-Score: 238.34
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 3/10

vs
industry
vs
history
Operating margin (%) -55180.00
CYTR's Operating margin (%) is ranked lower than
98% of the 651 Companies
in the Global Biotechnology industry.

( Industry Median: -73.33 vs. CYTR: -55180.00 )
Ranked among companies with meaningful Operating margin (%) only.
CYTR' s 10-Year Operating margin (%) Range
Min: -49606   Max: -21.16
Current: -55180

-49606
-21.16
Net-margin (%) -52307.00
CYTR's Net-margin (%) is ranked lower than
97% of the 651 Companies
in the Global Biotechnology industry.

( Industry Median: -71.50 vs. CYTR: -52307.00 )
Ranked among companies with meaningful Net-margin (%) only.
CYTR' s 10-Year Net-margin (%) Range
Min: -30118   Max: 408
Current: -52307

-30118
408
ROE (%) -69.01
CYTR's ROE (%) is ranked lower than
73% of the 756 Companies
in the Global Biotechnology industry.

( Industry Median: -27.51 vs. CYTR: -69.01 )
Ranked among companies with meaningful ROE (%) only.
CYTR' s 10-Year ROE (%) Range
Min: -342.91   Max: 1.39
Current: -69.01

-342.91
1.39
ROA (%) -54.87
CYTR's ROA (%) is ranked lower than
74% of the 836 Companies
in the Global Biotechnology industry.

( Industry Median: -23.47 vs. CYTR: -54.87 )
Ranked among companies with meaningful ROA (%) only.
CYTR' s 10-Year ROA (%) Range
Min: -201.4   Max: 1.13
Current: -54.87

-201.4
1.13
ROC (Joel Greenblatt) (%) -8786.62
CYTR's ROC (Joel Greenblatt) (%) is ranked lower than
86% of the 808 Companies
in the Global Biotechnology industry.

( Industry Median: -358.68 vs. CYTR: -8786.62 )
Ranked among companies with meaningful ROC (Joel Greenblatt) (%) only.
CYTR' s 10-Year ROC (Joel Greenblatt) (%) Range
Min: -12894.39   Max: -45.66
Current: -8786.62

-12894.39
-45.66
Revenue Growth (3Y)(%) -100.00
CYTR's Revenue Growth (3Y)(%) is ranked lower than
92% of the 396 Companies
in the Global Biotechnology industry.

( Industry Median: -0.40 vs. CYTR: -100.00 )
Ranked among companies with meaningful Revenue Growth (3Y)(%) only.
CYTR' s 10-Year Revenue Growth (3Y)(%) Range
Min: -100   Max: 188.4
Current: -100

-100
188.4
EBITDA Growth (3Y)(%) -10.30
CYTR's EBITDA Growth (3Y)(%) is ranked lower than
58% of the 426 Companies
in the Global Biotechnology industry.

( Industry Median: -5.00 vs. CYTR: -10.30 )
Ranked among companies with meaningful EBITDA Growth (3Y)(%) only.
CYTR' s 10-Year EBITDA Growth (3Y)(%) Range
Min: -67.3   Max: 144.7
Current: -10.3

-67.3
144.7
EPS Growth (3Y)(%) -11.70
CYTR's EPS Growth (3Y)(%) is ranked lower than
54% of the 413 Companies
in the Global Biotechnology industry.

( Industry Median: -7.70 vs. CYTR: -11.70 )
Ranked among companies with meaningful EPS Growth (3Y)(%) only.
CYTR' s 10-Year EPS Growth (3Y)(%) Range
Min: -55.3   Max: 94.8
Current: -11.7

-55.3
94.8
» CYTR's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Guru Trades

CYTR Guru Trades in

Q4 2013

CYTR Guru Trades in Q4 2013

Steven Cohen 205,100 sh (New)
» More
Q1 2014

CYTR Guru Trades in Q1 2014

George Soros 81,800 sh (New)
Paul Tudor Jones 51,898 sh (New)
Steven Cohen Sold Out
» More
Q2 2014

CYTR Guru Trades in Q2 2014

George Soros Sold Out
Paul Tudor Jones Sold Out
» More
» Details

Insider Trades

Latest Guru Trades with CYTR

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Ratios

vs
industry
vs
history
P/B 4.40
CYTR's P/B is ranked higher than
52% of the 1028 Companies
in the Global Biotechnology industry.

( Industry Median: 4.60 vs. CYTR: 4.40 )
Ranked among companies with meaningful P/B only.
CYTR' s 10-Year P/B Range
Min: 1.3   Max: 64.65
Current: 4.4

1.3
64.65
P/S 2228.80
CYTR's P/S is ranked lower than
110% of the 1029 Companies
in the Global Biotechnology industry.

( Industry Median: 11.92 vs. CYTR: 2228.80 )
Ranked among companies with meaningful P/S only.
CYTR' s 10-Year P/S Range
Min: 0   Max: 2290.2
Current: 2228.8

0
2290.2
Current Ratio 3.24
CYTR's Current Ratio is ranked lower than
59% of the 809 Companies
in the Global Biotechnology industry.

( Industry Median: 4.36 vs. CYTR: 3.24 )
Ranked among companies with meaningful Current Ratio only.
CYTR' s 10-Year Current Ratio Range
Min: 1.04   Max: 41.14
Current: 3.24

1.04
41.14
Quick Ratio 3.24
CYTR's Quick Ratio is ranked lower than
56% of the 809 Companies
in the Global Biotechnology industry.

( Industry Median: 4.13 vs. CYTR: 3.24 )
Ranked among companies with meaningful Quick Ratio only.
CYTR' s 10-Year Quick Ratio Range
Min: 1.04   Max: 41.14
Current: 3.24

1.04
41.14
Days Sales Outstanding 19.00
CYTR's Days Sales Outstanding is ranked higher than
84% of the 558 Companies
in the Global Biotechnology industry.

( Industry Median: 63.44 vs. CYTR: 19.00 )
Ranked among companies with meaningful Days Sales Outstanding only.
CYTR' s 10-Year Days Sales Outstanding Range
Min: 2.32   Max: 7752.6
Current: 19

2.32
7752.6

Valuation & Return

vs
industry
vs
history
Price/Net Cash 5.20
CYTR's Price/Net Cash is ranked higher than
83% of the 820 Companies
in the Global Biotechnology industry.

( Industry Median: 9.70 vs. CYTR: 5.20 )
Ranked among companies with meaningful Price/Net Cash only.
CYTR' s 10-Year Price/Net Cash Range
Min: 0.55   Max: 458
Current: 5.2

0.55
458
Price/Net Current Asset Value 4.80
CYTR's Price/Net Current Asset Value is ranked higher than
84% of the 861 Companies
in the Global Biotechnology industry.

( Industry Median: 15.30 vs. CYTR: 4.80 )
Ranked among companies with meaningful Price/Net Current Asset Value only.
CYTR' s 10-Year Price/Net Current Asset Value Range
Min: 0.43   Max: 108.89
Current: 4.8

0.43
108.89
Price/Tangible Book 4.30
CYTR's Price/Tangible Book is ranked higher than
73% of the 1026 Companies
in the Global Biotechnology industry.

( Industry Median: 5.70 vs. CYTR: 4.30 )
Ranked among companies with meaningful Price/Tangible Book only.
CYTR' s 10-Year Price/Tangible Book Range
Min: 0.32   Max: 65.43
Current: 4.3

0.32
65.43
Earnings Yield (Greenblatt) -34.40
CYTR's Earnings Yield (Greenblatt) is ranked lower than
88% of the 1030 Companies
in the Global Biotechnology industry.

( Industry Median: -6.70 vs. CYTR: -34.40 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) only.
CYTR' s 10-Year Earnings Yield (Greenblatt) Range
Min: -97   Max: 3114.3
Current: -34.4

-97
3114.3

Business Description

Industry: Biotechnology » Biotechnology
Compare:NVO, AMGN, GILD, BIIB, CELG » details
Traded in other countries:CX5N.Germany,
CytRx Corp is a Delaware corporation, incorporated in 1985. The Company is a biopharmaceutical research and development company specializing in oncology. Its oncology pipeline includes three clinical-stage drug candidates in various stages of development: Aldoxorubicin, Tamibarotene, and Bafetinib. Aldoxorubicin is a conjugate of the commonly prescribed chemotherapeutic agent doxorubicin that binds to circulating albumin in the bloodstream and is concentrated at the site of tumors. Tamibarotene is an orally available, synthetic retinoid, rationally designed to overcome resistance and reduce the toxic side effects of differentiation therapy with all-trans retinoic acid, a component of the current first-line treatment for acute promyelocytic leukemia, or APL. Bafetinib (formerly INNO-406) is an orally bioavailable, rationally-designed inhibitor of several Src kinases developed by the Japanese pharmaceutical company, Nippon Shinyaku, to overcome some of the limitations of Gleevec and other tyrosine kinase inhibitors in resistant chronic myelogenous leukemia. The Company do not have manufacture supplies of aldoxorubicin or any of our other product candidates accordingly it is dependent upon third-party manufactures, or potential future strategic alliance partners, to manufacture these supplies. The Company has manufacturing supply arrangements in place with respect to a portion of the clinical supplies needed for the clinical development programs for aldoxorubicin. The Company's plan is to establish its own sales force and marketing capability in order to commercialize aldoxorubicin in the U.S. and to seek a marketing partner for commercialization in other territories. It is subjected to a variety of federal, state and local regulations relating to the use, handling, storage and disposal of hazardous materials, including chemicals and radioactive and biological materials.

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
FEEDBACK